We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Partners to Seek Novel Drugs to Treat Fibrotic Diseases

By LabMedica International staff writers
Posted on 26 Jul 2015
Print article
A global biopharmaceutical company and an American university hospital-based research institute have agreed to collaborate on the diagnosis and cure of fibrotic diseases.

Fibrotic diseases such as scleroderma, renal fibrosis, and idiopathic pulmonary fibrosis are characterized by the gradual formation of excess fibrous connective tissue in an organ or tissue.

The Medical University of South Carolina (Charleston, USA) and the global pharmaceutical company Bristol-Myers Squibb (New York, NY, USA) announced that they have entered into a translational research collaboration focused on identifying novel medicines to halt or slow the progression of fibrotic disease. The agreement also provides for studies designed to improve the mechanistic understanding of fibrosis and to explore patient segmentation based on disease characteristics and/or biomarker approaches and predictors of disease progression.

“Bristol-Myers Squibb’s collaboration with the Medical University of South Carolina further strengthens and advances our discovery research efforts in fibrotic diseases, a strategic area of focus for the company,” said Dr. Carl Decicco, head of discovery research and development at Bristol-Myers Squibb. “The Medical University of South Carolina brings substantial expertise in translational research and drug discovery related to fibrotic diseases including access to patient derived disease tissue samples that will help us accelerate the application of scientific knowledge to potential new treatment approaches for patients.”

“This is an exciting opportunity with the potential to make a significant impact in fibrotic diseases and in patients’ lives with these debilitating diseases,” said Dr. Karen Lackey, associate professor of pharmacy and executive director for therapeutic discovery development at the Medical University of South Carolina. “Our goal with translational research is to shorten the timeline in getting patients the medications and treatments they need. We have unparalleled expertise in fibrosis research at the Medical University of South Carolina, and this collaboration with a leader like Bristol-Myers Squibb in discovery and development of medications is going to take that foundational work to the next level.”

Related Links:

The Medical University of South Carolina
Bristol-Myers Squibb


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.